Efficacy of an orlistat‐resveratrol combination for weight loss in subjects with obesity: A randomized controlled trial
Objective To evaluate the efficacy of an orlistat‐resveratrol (O‐R) combination in subjects with obesity over a 6‐month period. Methods This study was a double‐blind, parallel, randomized controlled clinical trial. Patients fulfilling the selection criteria (age from 20 to 60 years and body mass ind...
Saved in:
Published in | Obesity (Silver Spring, Md.) Vol. 24; no. 7; pp. 1454 - 1463 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
United States
Blackwell Publishing Ltd
01.07.2016
|
Subjects | |
Online Access | Get full text |
ISSN | 1930-7381 1930-739X 1930-739X |
DOI | 10.1002/oby.21523 |
Cover
Abstract | Objective
To evaluate the efficacy of an orlistat‐resveratrol (O‐R) combination in subjects with obesity over a 6‐month period.
Methods
This study was a double‐blind, parallel, randomized controlled clinical trial. Patients fulfilling the selection criteria (age from 20 to 60 years and body mass index (BMI) ≥30 and ≤39.9 kg/m2) consumed an energy‐reduced diet with 500 fewer calories than their usual diet for 2 weeks. Then the participants were randomly assigned to four groups, placebo, resveratrol, orlistat, or O‐R, and they consumed the energy‐reduced diet for 6 months. The study consisted of seven visits. During each visit, a 24‐h recall was performed, along with measurements of anthropometric and serum biochemical parameters.
Results
A total of 161 participants were selected. Of these, 84 participants completed the study. A significant weight loss of −6.82 kg (95% CI −8.37 to −5.26) was observed in the O‐R group compared with −3.50 kg (−5.05 to −1.95, P = 0.021) in the placebo group. In contrast, the −6.02 kg (−7.68 to −4.36) orlistat and −4.68 kg (−6.64 to −2.71) resveratrol monotherapy losses did not significantly differ from the placebo. Significant decreases in BMI, waist circumference, fat mass, triglycerides, leptin, and leptin/adiponectin ratio were observed with the O‐R combination.
Conclusions
The O‐R combination was the most effective weight loss treatment. |
---|---|
AbstractList | To evaluate the efficacy of an orlistat-resveratrol (O-R) combination in subjects with obesity over a 6-month period.OBJECTIVETo evaluate the efficacy of an orlistat-resveratrol (O-R) combination in subjects with obesity over a 6-month period.This study was a double-blind, parallel, randomized controlled clinical trial. Patients fulfilling the selection criteria (age from 20 to 60 years and body mass index (BMI) ≥30 and ≤39.9 kg/m(2) ) consumed an energy-reduced diet with 500 fewer calories than their usual diet for 2 weeks. Then the participants were randomly assigned to four groups, placebo, resveratrol, orlistat, or O-R, and they consumed the energy-reduced diet for 6 months. The study consisted of seven visits. During each visit, a 24-h recall was performed, along with measurements of anthropometric and serum biochemical parameters.METHODSThis study was a double-blind, parallel, randomized controlled clinical trial. Patients fulfilling the selection criteria (age from 20 to 60 years and body mass index (BMI) ≥30 and ≤39.9 kg/m(2) ) consumed an energy-reduced diet with 500 fewer calories than their usual diet for 2 weeks. Then the participants were randomly assigned to four groups, placebo, resveratrol, orlistat, or O-R, and they consumed the energy-reduced diet for 6 months. The study consisted of seven visits. During each visit, a 24-h recall was performed, along with measurements of anthropometric and serum biochemical parameters.A total of 161 participants were selected. Of these, 84 participants completed the study. A significant weight loss of -6.82 kg (95% CI -8.37 to -5.26) was observed in the O-R group compared with -3.50 kg (-5.05 to -1.95, P = 0.021) in the placebo group. In contrast, the -6.02 kg (-7.68 to -4.36) orlistat and -4.68 kg (-6.64 to -2.71) resveratrol monotherapy losses did not significantly differ from the placebo. Significant decreases in BMI, waist circumference, fat mass, triglycerides, leptin, and leptin/adiponectin ratio were observed with the O-R combination.RESULTSA total of 161 participants were selected. Of these, 84 participants completed the study. A significant weight loss of -6.82 kg (95% CI -8.37 to -5.26) was observed in the O-R group compared with -3.50 kg (-5.05 to -1.95, P = 0.021) in the placebo group. In contrast, the -6.02 kg (-7.68 to -4.36) orlistat and -4.68 kg (-6.64 to -2.71) resveratrol monotherapy losses did not significantly differ from the placebo. Significant decreases in BMI, waist circumference, fat mass, triglycerides, leptin, and leptin/adiponectin ratio were observed with the O-R combination.The O-R combination was the most effective weight loss treatment.CONCLUSIONSThe O-R combination was the most effective weight loss treatment. Objective To evaluate the efficacy of an orlistat‐resveratrol (O‐R) combination in subjects with obesity over a 6‐month period. Methods This study was a double‐blind, parallel, randomized controlled clinical trial. Patients fulfilling the selection criteria (age from 20 to 60 years and body mass index (BMI) ≥30 and ≤39.9 kg/m2) consumed an energy‐reduced diet with 500 fewer calories than their usual diet for 2 weeks. Then the participants were randomly assigned to four groups, placebo, resveratrol, orlistat, or O‐R, and they consumed the energy‐reduced diet for 6 months. The study consisted of seven visits. During each visit, a 24‐h recall was performed, along with measurements of anthropometric and serum biochemical parameters. Results A total of 161 participants were selected. Of these, 84 participants completed the study. A significant weight loss of −6.82 kg (95% CI −8.37 to −5.26) was observed in the O‐R group compared with −3.50 kg (−5.05 to −1.95, P = 0.021) in the placebo group. In contrast, the −6.02 kg (−7.68 to −4.36) orlistat and −4.68 kg (−6.64 to −2.71) resveratrol monotherapy losses did not significantly differ from the placebo. Significant decreases in BMI, waist circumference, fat mass, triglycerides, leptin, and leptin/adiponectin ratio were observed with the O‐R combination. Conclusions The O‐R combination was the most effective weight loss treatment. To evaluate the efficacy of an orlistat-resveratrol (O-R) combination in subjects with obesity over a 6-month period. This study was a double-blind, parallel, randomized controlled clinical trial. Patients fulfilling the selection criteria (age from 20 to 60 years and body mass index (BMI) ≥30 and ≤39.9 kg/m(2) ) consumed an energy-reduced diet with 500 fewer calories than their usual diet for 2 weeks. Then the participants were randomly assigned to four groups, placebo, resveratrol, orlistat, or O-R, and they consumed the energy-reduced diet for 6 months. The study consisted of seven visits. During each visit, a 24-h recall was performed, along with measurements of anthropometric and serum biochemical parameters. A total of 161 participants were selected. Of these, 84 participants completed the study. A significant weight loss of -6.82 kg (95% CI -8.37 to -5.26) was observed in the O-R group compared with -3.50 kg (-5.05 to -1.95, P = 0.021) in the placebo group. In contrast, the -6.02 kg (-7.68 to -4.36) orlistat and -4.68 kg (-6.64 to -2.71) resveratrol monotherapy losses did not significantly differ from the placebo. Significant decreases in BMI, waist circumference, fat mass, triglycerides, leptin, and leptin/adiponectin ratio were observed with the O-R combination. The O-R combination was the most effective weight loss treatment. To evaluate the efficacy of an orlistat-resveratrol (O-R) combination in subjects with obesity over a 6-month period. This study was a double-blind, parallel, randomized controlled clinical trial. Patients fulfilling the selection criteria (age from 20 to 60 years and body mass index (BMI) ≥30 and ≤39.9 kg/m^sup 2^) consumed an energy-reduced diet with 500 fewer calories than their usual diet for 2 weeks. Then the participants were randomly assigned to four groups, placebo, resveratrol, orlistat, or O-R, and they consumed the energy-reduced diet for 6 months. The study consisted of seven visits. During each visit, a 24-h recall was performed, along with measurements of anthropometric and serum biochemical parameters. A total of 161 participants were selected. Of these, 84 participants completed the study. A significant weight loss of -6.82 kg (95% CI -8.37 to -5.26) was observed in the O-R group compared with -3.50 kg (-5.05 to -1.95, P = 0.021) in the placebo group. In contrast, the -6.02 kg (-7.68 to -4.36) orlistat and -4.68 kg (-6.64 to -2.71) resveratrol monotherapy losses did not significantly differ from the placebo. Significant decreases in BMI, waist circumference, fat mass, triglycerides, leptin, and leptin/adiponectin ratio were observed with the O-R combination. The O-R combination was the most effective weight loss treatment. |
Author | García‐Salgado López, Enrique Raúl Arzola‐Paniagua, María Angélica Calvo‐Vargas, Cesar G. Guevara‐Cruz, Martha |
Author_xml | – sequence: 1 givenname: María Angélica surname: Arzola‐Paniagua fullname: Arzola‐Paniagua, María Angélica organization: Instituto Biosen A.C – sequence: 2 givenname: Enrique Raúl surname: García‐Salgado López fullname: García‐Salgado López, Enrique Raúl organization: Instituto Biosen A.C – sequence: 3 givenname: Cesar G. surname: Calvo‐Vargas fullname: Calvo‐Vargas, Cesar G. organization: Centro de Diseño y Planeación en Investigación Médica S.C – sequence: 4 givenname: Martha surname: Guevara‐Cruz fullname: Guevara‐Cruz, Martha organization: Instituto Nacional de Ciencias Médicas y Nutrición |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27221771$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kcFO3DAURa0KVGDaRX-gstQNLAae7SRO2AGigITEppXaVeQ4dvHIscF2GIUVn8A39kvwMMACqV29tzj3vqd7d9CG804h9IXAPgGgB76b9ikpKfuAtknDYM5Z82vjba_JFtqJcQFQVFCSj2iLckoJ52QbTadaGynkhL3GwmEfrIlJpL8Pj0HFOxVECt5i6YfOOJGMd1j7gJfK_LlO2PoYsXE4jt1CyRTx0qRr7DsVTZoO8REOwvV-MPeqzxZuZWXzmoIR9hPa1MJG9fllztDP76c_Ts7nl1dnFydHl3NZlDWb94wKEFQwqLpKlaQuagacS1o1FaiyKbqq5h2RFVFallJTXWvZs7IhQvcCgM3Q7tr3JvjbUcXUDiZKZa1wyo-xJTUAoQ3kYzP07R268GNw-bsVxYuaU15m6usLNXaD6tubYAYRpvY11AzsrQEZcj5B6TeEQLsqrM2Ftc-FZfbgHStNes45BWHs_xRLY9X0b-v26vj3WvEEBUGolw |
CitedBy_id | crossref_primary_10_2174_1573399815666191113125247 crossref_primary_10_1016_j_endmts_2025_100218 crossref_primary_10_1016_j_jff_2019_103646 crossref_primary_10_3389_fendo_2019_00413 crossref_primary_10_3390_nu14102053 crossref_primary_10_1016_j_jep_2023_116789 crossref_primary_10_3390_nu14071424 crossref_primary_10_1186_s13765_022_00712_y crossref_primary_10_1016_j_clnesp_2020_11_025 crossref_primary_10_1016_j_clnu_2020_01_002 crossref_primary_10_3390_endocrines3020023 crossref_primary_10_1080_10408398_2018_1529654 crossref_primary_10_2174_0929867330666230517124033 crossref_primary_10_3390_ijms21165642 crossref_primary_10_3390_life13010108 crossref_primary_10_1080_07357907_2022_2115057 crossref_primary_10_3390_ijms22095047 crossref_primary_10_1002_14651858_CD015861 crossref_primary_10_1186_s12944_020_1198_x crossref_primary_10_1016_j_mvr_2020_104054 crossref_primary_10_1038_s41366_021_00921_3 crossref_primary_10_1016_j_molmet_2024_102002 crossref_primary_10_1111_obr_12775 crossref_primary_10_1016_j_lfs_2020_117962 crossref_primary_10_1016_j_phrs_2017_01_012 crossref_primary_10_3390_ijms25020747 crossref_primary_10_3390_ijms23074027 crossref_primary_10_1089_met_2022_0052 crossref_primary_10_1002_med_21565 crossref_primary_10_1016_j_phyplu_2024_100526 crossref_primary_10_1002_lipd_12196 crossref_primary_10_1039_C9FO00293F crossref_primary_10_1007_s10555_022_10056_0 crossref_primary_10_1080_10408398_2022_2159921 crossref_primary_10_1007_s11154_019_09494_z crossref_primary_10_3389_fphys_2022_795980 crossref_primary_10_3389_fnut_2023_1140019 crossref_primary_10_3390_nu13020672 crossref_primary_10_1177_1973798X241289779 crossref_primary_10_3390_nu10111651 crossref_primary_10_1007_s13105_018_0648_7 crossref_primary_10_1080_10408398_2021_1875980 crossref_primary_10_1186_s12944_024_02214_w crossref_primary_10_1016_j_biopha_2021_111282 crossref_primary_10_1002_ptr_8319 crossref_primary_10_1016_j_phrs_2017_12_033 crossref_primary_10_1080_07388551_2024_2424362 |
Cites_doi | 10.1007/s00018-014-1808-8 10.1155/2011/285618 10.1007/s12079-014-0257-3 10.1016/j.bbadis.2014.11.012 10.1038/oby.2004.282 10.1016/j.bcp.2008.11.027 10.1002/oby.20030 10.1073/pnas.0610068104 10.1016/j.phrs.2013.03.011 10.1016/j.ejcb.2008.08.003 10.1016/j.jnutbio.2013.09.001 10.3389/fphar.2015.00079 10.1038/sj.ijo.0803606 10.1016/j.cmet.2011.10.002 10.1038/ijo.2015.23 10.1016/j.numecd.2010.03.003 10.1139/apnm-2015-0075 10.1016/j.biochi.2012.01.008 10.1016/S0024-3205(99)00410-5 10.1002/oby.20263 10.1111/obr.12318 10.1161/circ.106.25.3143 10.1093/ajcn/55.1.309s 10.2337/diacare.27.10.2488 10.1002/oby.20394 10.1111/j.1365-2796.2006.01702.x 10.1097/01.crd.0000380842.14048.7e 10.1016/j.cell.2012.01.017 10.1016/j.atherosclerosis.2009.08.020 10.3389/fphar.2015.00199 10.1017/S0007114511002753 10.1155/2013/136584 10.1016/j.phrs.2011.07.004 10.1016/j.ejim.2012.06.013 |
ContentType | Journal Article |
Copyright | 2016 The Obesity Society 2016 The Obesity Society. Copyright Blackwell Publishing Ltd. Jul 2016 |
Copyright_xml | – notice: 2016 The Obesity Society – notice: 2016 The Obesity Society. – notice: Copyright Blackwell Publishing Ltd. Jul 2016 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM K9. 7X8 |
DOI | 10.1002/oby.21523 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE ProQuest Health & Medical Complete (Alumni) |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1930-739X |
EndPage | 1463 |
ExternalDocumentID | 4131614221 27221771 10_1002_oby_21523 OBY21523 |
Genre | article Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article Feature |
GrantInformation_xml | – fundername: Laboratorios Senosiain |
GroupedDBID | --- 05W 0R~ 123 1OC 24P 29N 2FS 2WC 31~ 33P 39C 3SF 3V. 4.4 50Y 52U 52V 53G 70F 7X7 8-1 8C1 A00 AAESR AAEVG AAFWJ AAHBH AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AASGY AAWTL AAXRX AAYCA AAZKR ABCUV ABIVO ABJNI ABLJU ABQWH ABXGK ACAHQ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFKRA AFPWT AFWVQ AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZQEC AZVAB BAWUL BENPR BFHJK BHBCM BKNYI BMXJE BOGZA BPHCQ BRXPI BVXVI CS3 DCZOG DIK DPXWK DRFUL DRMAN DRSTM DU5 E3Z EBS EJD EMOBN F5P FUBAC FYUFA G-S GODZA HGLYW HZ~ KBYEO LATKE LEEKS LH4 LITHE LOXES LUTES LW6 LYRES M0R M1P MEWTI MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM MY~ O66 O9- OK1 P2W PQQKQ PROAC PSQYO R.K ROL SUPJJ UKHRP WBKPD WHG WHWMO WIH WIJ WIK WIN WOHZO WOQ WQJ WVDHM WXSBR WYJ YHZ AAYXX AEYWJ AGHNM AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY CGR CUY CVF ECM EIF NPM K9. 7X8 |
ID | FETCH-LOGICAL-c4583-d32a0a2a306b6e518483077c26960e594b687b1c61efc5cf2f8fcd3591afda003 |
ISSN | 1930-7381 1930-739X |
IngestDate | Fri Sep 05 11:32:42 EDT 2025 Fri Jul 25 23:52:08 EDT 2025 Mon Jul 21 05:59:47 EDT 2025 Thu Apr 24 22:55:34 EDT 2025 Tue Jul 01 01:16:19 EDT 2025 Wed Jan 22 16:49:10 EST 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Language | English |
License | 2016 The Obesity Society. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c4583-d32a0a2a306b6e518483077c26960e594b687b1c61efc5cf2f8fcd3591afda003 |
Notes | National Clinical Trial Registry (Registro Nacional de Ensayos Clinicos—RNEC) of Mexico identifier 133300410A0152 (ECORL/RES‐052013) Clinical trial registration The authors declared no conflict of interest. Disclosure Funding agencies Laboratorios Senosiain S.A. de C.V. MAAP: protocol development, surveillance of the study follow‐up, manuscript writing, manuscript review; ERGSL: protocol development, manuscript writing, manuscript review; CGCV: patient selection, treatment follow‐up, surveillance of the dietary and pharmacological treatment, data collection; MGC: protocol development, statistical analysis, writing and editing/review of the manuscript. Author contributions SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.21523 |
PMID | 27221771 |
PQID | 1807487275 |
PQPubID | 105348 |
PageCount | 10 |
ParticipantIDs | proquest_miscellaneous_1800129058 proquest_journals_1807487275 pubmed_primary_27221771 crossref_primary_10_1002_oby_21523 crossref_citationtrail_10_1002_oby_21523 wiley_primary_10_1002_oby_21523_OBY21523 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | July 2016 |
PublicationDateYYYYMMDD | 2016-07-01 |
PublicationDate_xml | – month: 07 year: 2016 text: July 2016 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Silver Spring |
PublicationTitle | Obesity (Silver Spring, Md.) |
PublicationTitleAlternate | Obesity (Silver Spring) |
PublicationYear | 2016 |
Publisher | Blackwell Publishing Ltd |
Publisher_xml | – name: Blackwell Publishing Ltd |
References | 2007; 104 2009; 88 2015; 39 2015; 6 2015; 16 2010; 209 2013; 21 2004; 27 2015; 72 2000; 66 2014; 25 2015; 1852 2011; 14 2007; 31 2012; 148 1992; 55 2012; 107 2012; 94 2009; 77 2011; 2011 39 2013; 2013 2015; 40 2013; 72 2004; 12 2011; 64 2002; 106 2011; 21 2014 2006; 260 2014; 8 2012; 23 2005; 13 1988 21 e_1_2_6_32_1 e_1_2_6_10_1 e_1_2_6_31_1 e_1_2_6_30_1 Lohman TG (e_1_2_6_25_1) 1988 e_1_2_6_19_1 Bray GA. (e_1_2_6_38_1); 21 e_1_2_6_13_1 e_1_2_6_36_1 e_1_2_6_14_1 e_1_2_6_35_1 e_1_2_6_11_1 e_1_2_6_34_1 e_1_2_6_12_1 e_1_2_6_33_1 e_1_2_6_18_1 e_1_2_6_15_1 e_1_2_6_16_1 e_1_2_6_37_1 e_1_2_6_21_1 e_1_2_6_20_1 Wicklow B (e_1_2_6_17_1) 2014 Grundy SM (e_1_2_6_24_1) 2005; 13 e_1_2_6_9_1 e_1_2_6_8_1 Lau DC (e_1_2_6_29_1); 39 e_1_2_6_5_1 e_1_2_6_4_1 e_1_2_6_7_1 e_1_2_6_6_1 e_1_2_6_3_1 e_1_2_6_23_1 e_1_2_6_2_1 e_1_2_6_22_1 e_1_2_6_28_1 e_1_2_6_27_1 e_1_2_6_26_1 |
References_xml | – volume: 12 start-page: 151S issue: Suppl year: 2004 end-page: 162S article-title: Efficacy of lifestyle modification for long‐term weight control publication-title: Obes Res – volume: 55 start-page: 309S year: 1992 end-page: 313S article-title: Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18‐0647 (tetrahydrolipstatin) publication-title: Am J Clin Nutr – volume: 106 start-page: 3143 year: 2002 end-page: 3421 article-title: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report publication-title: Circulation – volume: 8 start-page: 385 year: 2014 end-page: 391 article-title: Dose response biology of resveratrol in obesity publication-title: J Cell Commun Signal – volume: 13 start-page: 322 year: 2005 end-page: 327 article-title: Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary publication-title: Cardiol Rev – volume: 39 start-page: 967 year: 2015 end-page: 976 article-title: Resveratrol induces brown‐like adipocyte formation in white fat through activation of AMP‐activated protein kinase (AMPK) alpha1 publication-title: Int J Obes (Lond) – volume: 64 start-page: 438 year: 2011 end-page: 455 article-title: Dietary phytochemicals and their potential effects on obesity: a review publication-title: Pharmacol Res – volume: 31 start-page: 1442 year: 2007 end-page: 1448 article-title: Impact of weight loss on the metabolic syndrome publication-title: Int J Obes (Lond) – volume: 16 start-page: 1071 year: 2015 end-page: 1080 article-title: Effect of orlistat on glycaemic control in overweight and obese patients with type 2 diabetes mellitus: a systematic review and meta‐analysis of randomized controlled trials publication-title: Obes Rev – volume: 21 start-page: 893 end-page: 899 article-title: Why do we need drugs to treat the patient with obesity? publication-title: Obesity (Silver Spring) – volume: 72 start-page: 1473 year: 2015 end-page: 1488 article-title: Metabolic effects of resveratrol: addressing the controversies publication-title: Cell Mol Life Sci – volume: 14 start-page: 612 year: 2011 end-page: 622 article-title: Calorie restriction‐like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans publication-title: Cell Metab – volume: 148 start-page: 421 year: 2012 end-page: 433 article-title: Resveratrol ameliorates aging‐related metabolic phenotypes by inhibiting cAMP phosphodiesterases publication-title: Cell – volume: 209 start-page: 220 year: 2010 end-page: 225 article-title: Leptin, adiponectin, their ratio and risk of coronary heart disease: results from the MONICA/KORA Augsburg Study 1984‐2002 publication-title: Atherosclerosis – volume: 2011 start-page: 285618 year: 2011 article-title: Effect of plant polyphenols on adipokine secretion from human SGBS adipocytes publication-title: Biochem Res Int – volume: 6 start-page: 79 year: 2015 article-title: Obesity and inflammation: reduced cytokine expression due to resveratrol in a human in vitro model of inflamed adipose tissue publication-title: Front Pharmacol – volume: 2013 start-page: 136584 year: 2013 article-title: Mechanisms of chronic state of inflammation as mediators that link obese adipose tissue and metabolic syndrome publication-title: Mediat Inflamm – volume: 260 start-page: 388 year: 2006 end-page: 398 article-title: Evaluation of a primary care‐oriented brief counselling intervention for obesity with and without orlistat publication-title: J Intern Med – volume: 21 start-page: E154 year: 2013 end-page: E161 article-title: Obesity and body fat classification in the metabolic syndrome: impact on cardiometabolic risk metabotype publication-title: Obesity (Silver Spring) – volume: 21 start-page: E182 year: 2013 end-page: E189 article-title: Visceral fat resection in humans: effect on insulin sensitivity, beta‐cell function, adipokines, and inflammatory markers publication-title: Obesity (Silver Spring) – volume: 27 start-page: 2488 year: 2004 end-page: 2490 article-title: Leptin‐to‐adiponectin ratio as a potential atherogenic index in obese type 2 diabetic patients publication-title: Diabetes Care – volume: 72 start-page: 69 year: 2013 end-page: 82 article-title: One‐year supplementation with a grape extract containing resveratrol modulates inflammatory‐related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease publication-title: Pharmacol Res – year: 1988 – volume: 104 start-page: 7217 year: 2007 end-page: 7222 article-title: Resveratrol stimulates AMP kinase activity in neurons publication-title: Proc Natl Acad Sci USA – start-page: 1 year: 2014 end-page: 9 article-title: Proposed trial: safety and efficacy of resveratrol for the treatment of non‐alcoholic fatty liver disease (NAFLD) and associated insulin resistance in adolescents who are overweight or obese adolescents ‐ rationale and protocol publication-title: Biochem Cell Biol – volume: 39 start-page: S134 issue: Suppl 5 end-page: S141 article-title: Current and emerging pharmacotherapies for weight management in prediabetes and diabetes publication-title: Can J Diabetes – volume: 40 start-page: 1129 year: 2015 end-page: 1136 article-title: Resveratrol prevents insulin resistance caused by short‐term elevation of free fatty acids in vivo publication-title: Appl Physiol Nutr Metab – volume: 66 start-page: 663 year: 2000 end-page: 673 article-title: Biological effects of resveratrol publication-title: Life Sci – volume: 107 start-page: 202 year: 2012 end-page: 210 article-title: Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress publication-title: Br J Nutr – volume: 94 start-page: 2126 year: 2012 end-page: 2130 article-title: Up‐ and down‐regulation of adiponectin expression and multimerization: mechanisms and therapeutic implication publication-title: Biochimie – volume: 25 start-page: 1 year: 2014 end-page: 18 article-title: Novel insights of dietary polyphenols and obesity publication-title: J Nutr Biochem – volume: 23 start-page: 755 year: 2012 end-page: 759 article-title: The plasma leptin/adiponectin ratio predicts first cardiovascular event in men: a prospective nested case‐control study publication-title: Eur J Intern Med – volume: 21 start-page: 851 year: 2011 end-page: 856 article-title: Acute resveratrol supplementation improves flow‐mediated dilatation in overweight/obese individuals with mildly elevated blood pressure publication-title: Nutr Metab Cardiovasc Dis – volume: 1852 start-page: 1137 year: 2015 end-page: 1144 article-title: Resveratrol and obesity: can resveratrol relieve metabolic disturbances? publication-title: Biochim Biophys Acta – volume: 77 start-page: 1053 year: 2009 end-page: 1063 article-title: Long‐term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats publication-title: Biochem Pharmacol – volume: 88 start-page: 35 year: 2009 end-page: 44 article-title: Sirt1 increases skeletal muscle precursor cell proliferation publication-title: Eur J Cell Biol – volume: 6 start-page: 199 year: 2015 article-title: Systems pharmacology of adiposity reveals inhibition of EP300 as a common therapeutic mechanism of caloric restriction and resveratrol for obesity publication-title: Front Pharmacol – ident: e_1_2_6_8_1 doi: 10.1007/s00018-014-1808-8 – ident: e_1_2_6_14_1 doi: 10.1155/2011/285618 – ident: e_1_2_6_19_1 doi: 10.1007/s12079-014-0257-3 – ident: e_1_2_6_21_1 doi: 10.1016/j.bbadis.2014.11.012 – ident: e_1_2_6_37_1 doi: 10.1038/oby.2004.282 – ident: e_1_2_6_11_1 doi: 10.1016/j.bcp.2008.11.027 – ident: e_1_2_6_32_1 doi: 10.1002/oby.20030 – ident: e_1_2_6_7_1 doi: 10.1073/pnas.0610068104 – ident: e_1_2_6_16_1 doi: 10.1016/j.phrs.2013.03.011 – volume: 39 start-page: S134 issue: 5 ident: e_1_2_6_29_1 article-title: Current and emerging pharmacotherapies for weight management in prediabetes and diabetes publication-title: Can J Diabetes – ident: e_1_2_6_36_1 doi: 10.1016/j.ejcb.2008.08.003 – ident: e_1_2_6_28_1 doi: 10.1016/j.jnutbio.2013.09.001 – ident: e_1_2_6_22_1 doi: 10.3389/fphar.2015.00079 – ident: e_1_2_6_30_1 doi: 10.1038/sj.ijo.0803606 – ident: e_1_2_6_15_1 doi: 10.1016/j.cmet.2011.10.002 – ident: e_1_2_6_10_1 doi: 10.1038/ijo.2015.23 – ident: e_1_2_6_18_1 doi: 10.1016/j.numecd.2010.03.003 – ident: e_1_2_6_9_1 doi: 10.1139/apnm-2015-0075 – ident: e_1_2_6_13_1 doi: 10.1016/j.biochi.2012.01.008 – ident: e_1_2_6_6_1 doi: 10.1016/S0024-3205(99)00410-5 – ident: e_1_2_6_31_1 doi: 10.1002/oby.20263 – ident: e_1_2_6_4_1 doi: 10.1111/obr.12318 – ident: e_1_2_6_23_1 doi: 10.1161/circ.106.25.3143 – ident: e_1_2_6_3_1 doi: 10.1093/ajcn/55.1.309s – ident: e_1_2_6_34_1 doi: 10.2337/diacare.27.10.2488 – volume: 21 start-page: 893 ident: e_1_2_6_38_1 article-title: Why do we need drugs to treat the patient with obesity? publication-title: Obesity (Silver Spring) doi: 10.1002/oby.20394 – ident: e_1_2_6_26_1 doi: 10.1111/j.1365-2796.2006.01702.x – volume: 13 start-page: 322 year: 2005 ident: e_1_2_6_24_1 article-title: Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary publication-title: Cardiol Rev doi: 10.1097/01.crd.0000380842.14048.7e – ident: e_1_2_6_27_1 doi: 10.1016/j.cell.2012.01.017 – start-page: 1 year: 2014 ident: e_1_2_6_17_1 article-title: Proposed trial: safety and efficacy of resveratrol for the treatment of non‐alcoholic fatty liver disease (NAFLD) and associated insulin resistance in adolescents who are overweight or obese adolescents ‐ rationale and protocol publication-title: Biochem Cell Biol – ident: e_1_2_6_35_1 doi: 10.1016/j.atherosclerosis.2009.08.020 – volume-title: Anthropometric Standardization Reference Manual year: 1988 ident: e_1_2_6_25_1 – ident: e_1_2_6_20_1 doi: 10.3389/fphar.2015.00199 – ident: e_1_2_6_12_1 doi: 10.1017/S0007114511002753 – ident: e_1_2_6_2_1 doi: 10.1155/2013/136584 – ident: e_1_2_6_5_1 doi: 10.1016/j.phrs.2011.07.004 – ident: e_1_2_6_33_1 doi: 10.1016/j.ejim.2012.06.013 |
SSID | ssj0046051 |
Score | 2.3988805 |
Snippet | Objective
To evaluate the efficacy of an orlistat‐resveratrol (O‐R) combination in subjects with obesity over a 6‐month period.
Methods
This study was a... To evaluate the efficacy of an orlistat-resveratrol (O-R) combination in subjects with obesity over a 6-month period. This study was a double-blind, parallel,... To evaluate the efficacy of an orlistat-resveratrol (O-R) combination in subjects with obesity over a 6-month period. This study was a double-blind, parallel,... To evaluate the efficacy of an orlistat-resveratrol (O-R) combination in subjects with obesity over a 6-month period.OBJECTIVETo evaluate the efficacy of an... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1454 |
SubjectTerms | Adult Aged Anthropometry Anti-Obesity Agents - therapeutic use Body Mass Index Caloric Restriction Clinical trials Compliance Cytokines Diet Double-Blind Method Drug Therapy, Combination Energy Intake - drug effects FDA approval Female Glucose Humans Lactones - administration & dosage Lactones - therapeutic use Leptin - blood Lipids Male Metabolism Mexico Middle Aged Musculoskeletal system Nutrition research Obesity Obesity - blood Obesity - drug therapy Placebos Rodents Stilbenes - administration & dosage Stilbenes - therapeutic use Studies Treatment Outcome Triglycerides - blood Weight control Weight Loss |
Title | Efficacy of an orlistat‐resveratrol combination for weight loss in subjects with obesity: A randomized controlled trial |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Foby.21523 https://www.ncbi.nlm.nih.gov/pubmed/27221771 https://www.proquest.com/docview/1807487275 https://www.proquest.com/docview/1800129058 |
Volume | 24 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKkBAviDuFgQziAalyae4Jb13XbUDZEOtQ9xQ5iSOKSjKlTSf66znHdi7TijR4iSLXja2cL-fucwh56yW2cOPIYYEvLGYHwma-ESfMT2Mndi1XBLHM8j12j87sTzNn1um0KwSXq6gfb7aeK_kfqsIY0BVPyf4DZeuHwgDcA33hChSG641oPMb6D9ivHYP5oPcVC9QGVwxM6DUWS8YcdFgXjN8mpfBS-kJ7CxCO6OtYltFPmdAhHbK5bhMgj6uDFEvyX_ONSKqE9gXcyjYfbZVWtxZAVfV0jnnWPeUslK7WpN92NRQbMKTZV475fSXXR4VkqH6f94bwFxm1b6cPHcJ3qCewUzx2kuS9CQ7sWRfK9z3OClmC9huXw8M6Y2TEF-ucfcdGvqqMgljyomkldliKNS84GxXlRu9k9YO3nSCGWyfMVnw7sAbMs2RXXhBrW8Y0s1cHtjWovRbnNmxVzPqaSFElavPodx9bAFuN3KxyBY5PwoOzySScjmfTW-S26bkuttLY__i5Ugkw9myo9Aa1o6rE1cB8Xz_4qmJ0zdq5ajxJ7Wd6n9zTZgsdKgw-IB2RPSR3vujEjEfksoIizVPKM7oNirQFRQpQpAqKFKFI5xmtoEgRilRD8QMd0gaItAEilUB8TM4OxtPREdM9PViMEXqWWCYfcJODpRq5wjF82wcp48WmC6a0cAI7cn0vMmLXEMgtUjMFrpFYTmDwNOEggp6QnSzPxDNCMYKeOKbNE0uAWsojHgnDSkDnBSMkja0ueVe90DDWBe-x78oiVKW6zRDefSjffZe8qadeqCov2ybtVlQJNRNYhgYWk_LBCHC65HX9M7BojLvxTOSlnCPdvY7fJU8VNetVTM80Dc8zYLOSvH9fPjzZO5c3z2-w0Atyt_lMdsnOqijFS9CeV9Ericw_1VzGHg |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+of+an+orlistat-resveratrol+combination+for+weight+loss+in+subjects+with+obesity%3A+A+randomized+controlled+trial&rft.jtitle=Obesity+%28Silver+Spring%2C+Md.%29&rft.au=Arzola-Paniagua%2C+Mar%C3%ADa+Ang%C3%A9lica&rft.au=Garc%C3%ADa-Salgado+L%C3%B3pez%2C+Enrique+Ra%C3%BAl&rft.au=Calvo-Vargas%2C+Cesar+G&rft.au=Guevara-Cruz%2C+Martha&rft.date=2016-07-01&rft.issn=1930-739X&rft.eissn=1930-739X&rft.volume=24&rft.issue=7&rft.spage=1454&rft_id=info:doi/10.1002%2Foby.21523&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1930-7381&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1930-7381&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1930-7381&client=summon |